Literature DB >> 23638752

Cerebrospinal fluid levels of phosphorylated tau and Aβ1-38/Aβ1-40/Aβ1-42 in Alzheimer's disease with PS1 mutations.

Masaki Ikeda1, Kimie Yonemura, Satoko Kakuda, Yuichi Tashiro, Yukio Fujita, Eriko Takai, Yukiko Hashimoto, Kouki Makioka, Natsumi Furuta, Koichi Ishiguro, Risa Maruki, Jun'ichi Yoshida, Osamu Miyaguchi, Tamao Tsukie, Ryouzou Kuwano, Tsuneo Yamazaki, Haruyasu Yamaguchi, Masakuni Amari, Masamitsu Takatama, Yasuo Harigaya, Koichi Okamoto.   

Abstract

We studied seven cases of Alzheimer's disease (AD). Six of the patients had presenilin 1 (PS1) mutations (PS1AD). Three novel PS1 mutations (T99A, H131R and L219R) and three other missense mutations (M233L, H163R and V272A) were found in the PS1AD group. We measured the levels of phosphorylated tau (ptau-181, ptau-199) and Aβ (Aβ1-42, Aβ1-40 and Aβ1-38) in the cerebrospinal fluid (CSF) of PS1AD patients, early-onset sporadic AD (EOSAD), late-onset sporadic AD (LOSAD) and non-demented subjects (ND). The CSF levels of Aβ1-42 in the three AD groups were significantly lower than those of the ND group (p < 0.0001). CSF levels of Aβ1-42 in the PS1AD group were significantly lower than those in the two sporadic AD groups. The Aβ1-40 and Aβ1-38 levels in the CSF of the PS1AD group were significantly lower than those of the three other groups (p < 0.0001, respectively). The levels of Aβ1-40, Aβ1-38 and Aβ1-42 in the CSF of the PS1AD group remained lower than those of the ND group for 4 years. Not only CSF Aβ1-42, but also Aβ1-40 and Aβ1-38 decreased in the advanced stages of PS1AD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23638752     DOI: 10.3109/13506129.2013.790810

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  5 in total

1.  Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease.

Authors:  Anne M Fagan; Chengjie Xiong; Mateusz S Jasielec; Randall J Bateman; Alison M Goate; Tammie L S Benzinger; Bernardino Ghetti; Ralph N Martins; Colin L Masters; Richard Mayeux; John M Ringman; Martin N Rossor; Stephen Salloway; Peter R Schofield; Reisa A Sperling; Daniel Marcus; Nigel J Cairns; Virginia D Buckles; Jack H Ladenson; John C Morris; David M Holtzman
Journal:  Sci Transl Med       Date:  2014-03-05       Impact factor: 17.956

Review 2.  Autosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical AD.

Authors:  Suzanne Elizabeth Schindler; Anne M Fagan
Journal:  Front Neurol       Date:  2015-06-29       Impact factor: 4.003

Review 3.  Autophagy and Alzheimer's Disease: From Molecular Mechanisms to Therapeutic Implications.

Authors:  Md Sahab Uddin; Anna Stachowiak; Abdullah Al Mamun; Nikolay T Tzvetkov; Shinya Takeda; Atanas G Atanasov; Leandro B Bergantin; Mohamed M Abdel-Daim; Adrian M Stankiewicz
Journal:  Front Aging Neurosci       Date:  2018-01-30       Impact factor: 5.750

4.  Mutational analysis in familial Alzheimer's disease of Han Chinese in Taiwan with a predominant mutation PSEN1 p.Met146Ile.

Authors:  Yung-Shuan Lin; Chih-Ya Cheng; Yi-Chu Liao; Chen-Jee Hong; Jong-Ling Fuh
Journal:  Sci Rep       Date:  2020-11-13       Impact factor: 4.379

5.  Systematic validation of variants of unknown significance in APP, PSEN1 and PSEN2.

Authors:  Simon Hsu; Anna A Pimenova; Kimberly Hayes; Juan A Villa; Matthew J Rosene; Madhavi Jere; Alison M Goate; Celeste M Karch
Journal:  Neurobiol Dis       Date:  2020-02-19       Impact factor: 5.996

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.